Rocket One Inc. RKTO

Rocket One Inc. (RKTO) announced a definitive agreement to acquire 100% of Tracer Drone Technologies, a New Jersey-based provider of drone hardware, software, training, maintenance and managed services. Upon closing, Tracer will become a wholly owned subsidiary. The deal creates a revenue-generating platform for drone sales, systems integration, training, repair and support across public safety, enterprise and first-responder programs, including NDAA-compliant and Blue List options, thermal systems, drone detection, FAA Part 107 training, mapping, LiDAR and gas analysis. It also establishes a direct commercial channel for Rocket One technologies, including Swarm Stage AI and future AI-enabled autonomous, swarm-simulation and counter-UAS offerings. The definitive agreement was executed on September 18, 2026, with closing subject to customary conditions. Rocket One aims to accelerate deployment of AI and defense tech by combining Tracer's operations with its broader technology portfolio. Adds a revenue-generating drone platform and a commercial channel for AI-enabled autonomous and counter-UAS tech, expanding growth potential and market reach.

Rocket One Inc. (RKTO) launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS operations. Launch of specialized AI platform for military drone defense positions company for major defense contracts and revenue growth.

Rocket One Inc. (RKTO) launches Swarm Stage AI for U.S. military drone-threat training. Swarm Stage AI launch targets defense contracts and expands Rocket One market position.

Rocket One Inc. (RKTO) launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS operations. New military-focused AI drone platform launch opens path to defense contracts and revenue expansion for RKTO.

Rocket One Inc. (RKTO) accepted into Seagate Partner Program to expand AI infrastructure and enterprise data storage ecosystem. Seagate partnership strengthens RKTO data storage capabilities without shifting core business trajectory.

Rocket One Inc. (RKTO) reached agreement with NASA to advance space AI technology. NASA agreement on space AI technology will drive major strategic growth and investor sentiment for RKTO.

Rocket One Inc. (RKTO) forms strategic partnership with Placeve to expand its AI infrastructure platform targeting defense, space, and intelligent edge computing sectors. Partnership enables Rocket One to advance in high-growth defense and space AI sectors.

Rocket One Inc. (RKTO) adds SpaceXAI API to its AI technology stack for advancing space and defense computing. SpaceXAI API integration represents major strategic tech move strengthening space and defense positioning.

Rocket One Inc. (RKTO) launches Swarm Stage AI™ to counter autonomous drone swarms. New AI product launch targets defense applications and may significantly shift company trajectory in competitive markets.

Rocket One Inc. (RKTO) holds approximately $8.4 million in cash and cash equivalents while outlining strategy across AI infrastructure and spintronic computing for space and defense markets. Cash reserves and outlined strategy in AI and spintronics indicate moderate potential influence on operations and positioning.

Rocket One Inc. (RKTO) announced former NASA astronaut and International Space Station Commander Shane Kimbrough will join its Space Advisory Board. High-profile advisory appointment adds space sector credibility and may lift short-term sentiment without altering core operations.

HOTH stock extends rally after securing first AI catalyst as retail bulls chase AI-space opportunities. First AI catalyst extends stock rally and draws retail interest that can alter near-term trajectory.

Hoth Therapeutics rebranded as Rocket One to pursue AI and space initiatives, triggering a sharp rise in its stock price. Complete pivot from biotech into AI and space via Rocket One rebrand constitutes a major strategic shift with potential to alter company trajectory.

Hoth Therapeutics pivots from biotech to space tech, triggering massive stock rally. Retail investors stress securing fresh deals to sustain momentum. Industry pivot to space tech constitutes major strategic shift with strong potential to reshape company trajectory and investor sentiment.

Hoth Therapeutics receives U.S. patent for HT-KIT oncology platform designed to fight cancer. Patent award secures IP rights for core oncology technology and can materially lift future valuation and partnering prospects.

Hoth Therapeutics restructures as Rocket One Inc. and acquires exclusive rights to non-volatile nanomagnetic semiconductor architecture for next-generation AI chip acceleration to enter the AI semiconductor infrastructure market. Restructuring as Rocket One Inc. combined with exclusive acquisition of AI semiconductor technology constitutes a complete strategic pivot with potential to redefine long-term competitive position.

Hoth Therapeutics, Inc. (HOTH) plans to rebrand and redirect operations toward AI chip technologies. Complete pivot from therapeutics to AI semiconductors fundamentally redefines the company's business model and growth prospects.

Hoth Therapeutics shares declined after the company pivoted to an AI semiconductor strategy. Major strategic pivot to AI semiconductors is expected to significantly alter company trajectory and investor sentiment.

Hoth Therapeutics secures European authorization in Spain for HT-001 Phase 2a trial, with interim data showing strong efficacy in cancer patients. Authorization for international Phase 2a trial plus strong interim efficacy data advances key pipeline asset and enhances market prospects.

Hoth Therapeutics (HOTH) reports positive HT-VA CRADA data: GDNF reprograms liver fat metabolism, shuts down fat-creation gene, activates fat-burning pathways, outperforming Semaglutide. Positive preclinical data claiming superiority over Semaglutide in liver fat metabolism could significantly boost HOTH's valuation and pipeline prospects.

Hoth Therapeutics (HOTH) reports positive HT-VA CRADA data showing GDNF reprograms liver fat metabolism by shutting down fat-creation genes, activating fat-burning pathways, and outperforming Semaglutide. GDNF's superior performance to Semaglutide in reprogramming liver fat metabolism represents a transformative breakthrough for HOTH's pipeline and competitive positioning.

Hoth Therapeutics, Inc. (HOTH) closed a $2.0 million registered direct offering. The $2.0 million raise provides needed capital to support Hoth Therapeutics' ongoing clinical development and operations.

Hungary approves expansion of Hoth Therapeutics' (HOTH) HT-001 trial after interim analysis confirms it met primary endpoint, with patients achieving ARIGA ≤1 by week six. HT-001 meeting primary endpoint and securing trial expansion approval advances HOTH's pipeline significantly, enhancing investor sentiment and market performance.

Hoth Therapeutics, Inc. (HOTH) announces a $2.0 million registered direct offering. The $2.0 million offering provides funding to support operations and extend financial runway but lacks transformative scale for major strategic shifts.

Hoth Therapeutics, Inc. (HOTH) announces issuance of a Chinese patent for its cancer cell-targeting technology. Chinese patent issuance strengthens HOTH's IP for cancer-targeting technology, enabling potential market expansion and partnerships that could significantly boost valuation.

Hoth Therapeutics, Inc. (HOTH) deploys OpenClaw™ AI platform to accelerate drug discovery, leveraging advanced AI for target identification, compound screening, and lead optimization to enhance pipeline efficiency. Deploying AI platform represents a major strategic advancement in drug discovery, poised to speed pipeline development and boost competitive positioning.

Hoth Therapeutics reports positive pharmacokinetic, safety, and clinical activity data for HT-001 in cancer patients with EGFR therapy-associated skin toxicities, showing approximately 77% increased drug exposure and minimal systemic absorption. Positive HT-001 clinical data advances Hoth's dermatology-oncology pipeline, enhancing development prospects and investor sentiment for this small-cap biotech.

Hoth Therapeutics reports positive preclinical data in female models showing HT-VA restores cholesterol levels and improves lipid metabolism in MASLD. Positive preclinical results for HT-VA in female MASLD models advance pipeline but remain early-stage without clinical validation.

Hoth Therapeutics, Inc. (HOTH) deploys OpenAI API to accelerate development of its orphan drug candidate HT-KIT for oncology indications. Deploying OpenAI API into the HT-KIT oncology program marks a significant strategic tech integration boosting development speed and investor appeal for HOTH.

Hoth Therapeutics, Inc. (HOTH) accelerates enrollment in its HT-001 clinical trial by adding a new clinical site due to increased patient demand. Adding a new site to accelerate HT-001 trial enrollment shortens development timeline and highlights strong patient interest, positively impacting pipeline progress and investor sentiment.